Table 1.
Association between gGlu-HMRG fluorescence imaging and tumor-related factors and postoperative outcome.
| HCC | CRLM | |||||
|---|---|---|---|---|---|---|
| Low-gGlu-HMRG HCC (26 tumors) | High-gGlu-HMRG HCC (24 tumors) | P value | Low-gGlu-HMRG CRLM (22 tumors) | High-gGlu-HM | P value | |
| RG CRLM (23 tumors) | ||||||
| Preoperative blood examinations | ||||||
| GGT (U/L) | 44 (16–317)a | 50 (16–593) | 0.327 | 29 (13–436) | 64 (16–289) | 0.025 |
| ICGR15 (%) | 12.6 (5.6–41.2) | 11.0 (5.2–34.8) | 0.328 | 8.1 (4.0–20.7) | 7.95 (4.9–18.9) | 0.922 |
| Tumor markers | ||||||
| AFP (ng/mL) | 6.5 (1.9–4652.5) | 24.0 (3.0–139921.0) | 0.021 | — | — | — |
| DCP (mAU/mL) | 65 (9–27193) | 224 (8–64225) | 0.688 | — | — | — |
| CEA (ng/mL) | 3.9 (1.9–26.3) | 3.2 (1.0–8.2) | 0.381 | 14.3 (2.5–1087.8) | 24.8 (3.8–441.3) | 0.448 |
| CA19-9 (U/mL) | 18 (1–128) | 18 (1–74) | 0.991 | 16 (1–4825) | 39 (1–638) | 0.422 |
| Pathological findings | ||||||
| Tumor size (mm) | 25 (8–80) | 31 (9–98) | 0.236 | 23 (8–77) | 26 (8–160) | 0.524 |
| Tumor differentiation (well) | 11 (42%) | 6 (25%) | 0.197 | 6 (27%) | 7 (32%) | 0.741 |
| Vascular invasion (present) | 7 (27%) | 14 (58%) | 0.025 | — | — | — |
| LN metastasis (present) | — | — | — | 11 (58%) | 13 (65%) | 0.415 |
| UICC TNM stage (III and IV) | 1 (4%) | 3 (13%) | 0.296 | 17 (89%)b | 17 (85%)b | 0.676 |
| KRAS mutation (present) | — | — | — | 10 (53%) | 4 (20%) | 0.188 |
| Recurrence | ||||||
| Within 6 months of surgery, n (%) of patients | 2 (8%) | 5 (21%) | 0.220 | 3 (16%) | 9 (45%) | 0.048 |
aData are the median (range) or n (%) of the indicated number of tumors. bUICC 7th edition staging of primary colon cancer. HCC, hepatocellular carcinoma; CRLM, colorectal cancer liver metastasis; GGT, γ-glutamyltranspeptidase; ICGR15, indocyanine green retention test at 15 min; AFP, α-fetoprotein; DCP, des-gamma carboxy prothrombin; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9; LN, lymph node; UICC, Union of International Cancer Control.